{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021909","form_type":"8-K","ticker":"DH","cik":"0001861795","company_name":"Definitive Healthcare Corp.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.821454+00:00","generated_at":"2026-06-22T09:53:40.050543+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Definitive Healthcare Q3 revenue $57.4M (+33% YoY); net loss narrows; appoints Jon Maack as President","bullets":["Revenue $57.4M (+33% YoY), net loss $6.4M vs $21.0M; adjusted EBITDA $16.4M (29% revenue).","Q4 revenue guidance $58-59M (median +26% YoY); full-year 2022 revenue guidance $220-221M.","Jon Maack appointed President, effective Nov 3, 2022; reports to CEO; oversees product, engineering, strategy, M&A.","Maack received $400k base salary, 70% bonus target, 546k RSUs; previously Chief Strategy Officer at athenahealth.","Unlevered free cash flow $15.5M (27% revenue) in Q3; trailing twelve-month $67.4M (32% revenue)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021909","json":"https://secwatch.observer/filing/0000950170-22-021909.json","markdown":"https://secwatch.observer/filing/0000950170-22-021909.md","text":"https://secwatch.observer/filing/0000950170-22-021909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861795/000095017022021909/0000950170-22-021909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861795/000095017022021909/dh-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:53:40.050543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14ef74f96bbb9ba67dbc09e13c681edaaec999c1","claim":"Definitive Healthcare Corp. reported the third quarter ended September 30, 2022 results: revenue $57.4 million, net income ($6.4) million. Guidance raised.","evidence_excerpt":"EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2022 Third quarter revenue grew 33% year-over-year to $57.4 million Framingham, MA (November 3, 2022) – Definitive Healthcare Corp. (“Definitive Healthcare\" or the \"Company\") (Nasdaq: DH), an industry leader in healthcare commercial intelligence,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861795/000095017022021909/0000950170-22-021909-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$57.4 million"},{"label":"Net income","value":"($6.4) million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"933181168cd9bae7cc9db1c451b94e9b9bc110a9","claim":"Definitive Healthcare Corp. reported Full Year 2022 results: revenue in the range of $220 – $221 million, net income expected to be $30 – 31 million, EPS $0.19– $0.20. Guidance raised.","evidence_excerpt":"Revenue is expected to be in the range of $220 – $221 million, an increase of 33% from prior year at the midpoint.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861795/000095017022021909/0000950170-22-021909-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2022"},{"label":"Revenue","value":"in the range of $220 – $221 million"},{"label":"Net income","value":"expected to be $30 – 31 million"},{"label":"EPS","value":"$0.19– $0.20"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"baa1697711","claim":"Jonathan Maack was appointed as President at Definitive Healthcare Corp..","evidence_excerpt":"On November 3, 2022, the Company announced that, on September 16, 2022, its Board of Directors (the \"Board\") appointed Jonathan Maack to the position of President, effective November 3, 2022 (the \"Effective Date\").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861795/000095017022021909/0000950170-22-021909-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}